Literature DB >> 20800114

HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.

R Saenz1, C da Silva Souza, C-T Huang, M Larsson, S Esener, D Messmer.   

Abstract

There is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-γ, TNF-α, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800114      PMCID: PMC2963688          DOI: 10.1016/j.vaccine.2010.08.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  48 in total

Review 1.  The search for novel adjuvants for early life vaccinations: can "danger" motifs show us the way?

Authors:  J Kovarik; C A Siegrist
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2001       Impact factor: 4.291

2.  Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002.

Authors:  Howard Engers; Marie Paule Kieny; Pawan Malhotra; J Richard Pink
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

Review 3.  Vaccine adjuvants: current state and future trends.

Authors:  Nikolai Petrovsky; Julio César Aguilar
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

4.  Clinical setbacks for toll-like receptor 9 agonists in cancer.

Authors:  Charlie Schmidt
Journal:  Nat Biotechnol       Date:  2007-08-02       Impact factor: 54.908

5.  Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity.

Authors:  Corbin Clawson; Chien-Tze Huang; Diahnn Futalan; Daniel Martin Seible; Rebecca Saenz; Marie Larsson; Wenxue Ma; Boris Minev; Fiona Zhang; Mihri Ozkan; Cengiz Ozkan; Sadik Esener; Davorka Messmer
Journal:  Nanomedicine       Date:  2010-03-27       Impact factor: 5.307

6.  Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.

Authors:  Cagan Gurer; Till Strowig; Fabienne Brilot; Maggi Pack; Christine Trumpfheller; Frida Arrey; Chae Gyu Park; Ralph M Steinman; Christian Münz
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

Review 7.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

8.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.

Authors:  Christine Trumpfheller; Marina Caskey; Godwin Nchinda; Maria Paula Longhi; Olga Mizenina; Yaoxing Huang; Sarah J Schlesinger; Marco Colonna; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

9.  TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Authors:  B R Wong; R Josien; S Y Lee; B Sauter; H L Li; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

10.  Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.

Authors:  J Xu-Amano; H Kiyono; R J Jackson; H F Staats; K Fujihashi; P D Burrows; C O Elson; S Pillai; J R McGhee
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

View more
  19 in total

1.  Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization.

Authors:  R Saenz; B Messmer; D Futalan; Y Tor; M Larsson; G Daniels; S Esener; D Messmer
Journal:  Mol Immunol       Date:  2013-10-26       Impact factor: 4.407

2.  Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis.

Authors:  Jin-Cheng Zeng; Wen-Yu Xiang; Dong-Zi Lin; Jun-Ai Zhang; Gan-Bin Liu; Bin Kong; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Lai-Long Yi; Ji-Xin Zhong; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.

Authors:  Ajay Grover; Jolynn Troudt; Chad Foster; Randall Basaraba; Angelo Izzo
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

4.  Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans.

Authors:  Chunjian Qi; Yihua Cai; Lacey Gunn; Chuanlin Ding; Bing Li; Goetz Kloecker; Keqing Qian; John Vasilakos; Shinobu Saijo; Yoichiro Iwakura; John R Yannelli; Jun Yan
Journal:  Blood       Date:  2011-04-29       Impact factor: 22.113

5.  Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.

Authors:  Shuyun Dong; Tiefeng Xu; Peng Wang; Peng Zhao; Mingnan Chen
Journal:  Acta Pharmacol Sin       Date:  2017-04-17       Impact factor: 6.150

6.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

7.  Pentamers not found in the universal proteome can enhance antigen specific immune responses and adjuvant vaccines.

Authors:  Ami Patel; Jessica C Dong; Brett Trost; Jason S Richardson; Sarah Tohme; Shawn Babiuk; Anthony Kusalik; Sam K P Kung; Gary P Kobinger
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

8.  Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine.

Authors:  Xiancheng Zhang; Peng He; Zhongyu Hu; Xingtai Wang; Zhenglun Liang
Journal:  Virol J       Date:  2011-02-23       Impact factor: 4.099

9.  Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles.

Authors:  Diahnn F Campbell; Rebecca Saenz; Ila S Bharati; Daniel Seible; Liangfang Zhang; Sadik Esener; Bradley Messmer; Marie Larsson; Davorka Messmer
Journal:  Breast Cancer Res       Date:  2015-03-31       Impact factor: 6.466

10.  HMGB1: A Promising Therapeutic Target for Prostate Cancer.

Authors:  Munirathinam Gnanasekar; Ramaswamy Kalyanasundaram; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla
Journal:  Prostate Cancer       Date:  2013-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.